{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:41:36Z","timestamp":1793353296647,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014337","name":"Furthermore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jacc.2020.06.017","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T14:21:11Z","timestamp":1595859671000},"page":"518-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction"],"prefix":"10.1016","volume":"76","author":[{"given":"Dong Oh","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyonggin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun U","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonjee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woohyeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jah Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Young","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Oh","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Seog","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Ung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.06.017_bib1","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2020.06.017_bib2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.06.017_bib3","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2020.06.017_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2020.06.017_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.06.017_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.06.017_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/eurheartj\/ehv505","article-title":"Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"37","author":"Schmidt","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.06.017_bib8","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.112.112607","article-title":"Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study","volume":"126","author":"Olsen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.06.017_bib9","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","article-title":"Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study","volume":"123","author":"Schjerning Olsen","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.06.017_bib10","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.06.017_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.06.017_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.06.017_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.06.017_bib14","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","article-title":"Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction","volume":"113","author":"Gislason","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.06.017_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/hrt.2006.089367","article-title":"The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction","volume":"93","author":"Brophy","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2020.06.017_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction","volume":"313","author":"Schjerning Olsen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.06.017_bib17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","article-title":"Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study","volume":"157","author":"Mak","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2020.06.017_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2020.06.017_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"64","author":"Huo","year":"2019","journal-title":"Sci Bull"},{"key":"10.1016\/j.jacc.2020.06.017_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","article-title":"Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: Individual patient level landmark meta-analysis from seven RCTs","volume":"119","author":"Kang","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2020.06.017_bib21","doi-asserted-by":"crossref","DOI":"10.4178\/epih\/e2014008","article-title":"A\u00a0guide for the utilization of Health Insurance Review and Assessment Service national patient samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.jacc.2020.06.017_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/acr.23884","article-title":"Duration of symptom relief and early trajectory of adverse events for oral NSAIDs in knee osteoarthritis: a systematic review and meta-analysis","volume":"72","author":"Osani","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jacc.2020.06.017_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","article-title":"Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population","volume":"52","author":"Garcia Rodriguez","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.06.017_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2020.06.017_bib25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.06.017_bib26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"Capone","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.06.017_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clpt.2006.05.004","article-title":"Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease","volume":"80","author":"Renda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2020.06.017_bib28","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in\u00a0vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2020.06.017_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.105.568451","article-title":"Cyclooxygenase inhibition and cardiovascular risk","volume":"112","author":"Antman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.06.017_bib30","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.06.017_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4070\/kcj.2012.42.1.10","article-title":"Validity of the diagnosis of acute myocardial infarction in Korean national medical health insurance claims data: the Korean Heart Study (1)","volume":"42","author":"Kimm","year":"2012","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2020.06.017_bib32","first-page":"148","article-title":"Korean National Health Insurance value incentive program: achievements and future directions","volume":"45","author":"Kim","year":"2012","journal-title":"J\u00a0Prev Med Public Health"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720355728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720355728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:34:43Z","timestamp":1760016883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720355728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0735109720355728"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.06.017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738418842.793577481","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}